首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   441篇
  免费   52篇
  国内免费   27篇
耳鼻咽喉   6篇
儿科学   5篇
妇产科学   3篇
基础医学   39篇
口腔科学   118篇
临床医学   49篇
内科学   69篇
皮肤病学   2篇
神经病学   5篇
特种医学   4篇
外科学   57篇
综合类   82篇
预防医学   5篇
药学   41篇
中国医学   15篇
肿瘤学   20篇
  2023年   3篇
  2022年   8篇
  2021年   10篇
  2020年   9篇
  2019年   14篇
  2018年   11篇
  2017年   17篇
  2016年   18篇
  2015年   23篇
  2014年   28篇
  2013年   51篇
  2012年   43篇
  2011年   49篇
  2010年   35篇
  2009年   24篇
  2008年   28篇
  2007年   34篇
  2006年   36篇
  2005年   19篇
  2004年   31篇
  2003年   11篇
  2002年   9篇
  2001年   8篇
  2000年   1篇
排序方式: 共有520条查询结果,搜索用时 15 毫秒
1.
《Journal of endodontics》2019,45(12):1489-1495
IntroductionThe aim of the present study was to evaluate the effects of calcium hydroxide (Ca[OH]2), Ca(OH)2 + ibuprofen, and Ca(OH)2 + ciprofloxacin in terms of receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) levels in asymptomatic periapical lesions.MethodsSixty-six patients were randomly divided into 3 groups using a Web program according to the medication selected: Ca(OH)2, Ca(OH)2 + ibuprofen, and Ca(OH)2 + ciprofloxacin. After removing gutta-percha from the root canals, the RANKL and OPG samples were taken from the interstitial fluid of the apical tissues using 3 paper points. At the second appointment, medicaments were removed, and second sampling was performed using the same method. The RANKL and OPG levels were measured by the enzyme-linked immunosorbent assay, and the RANKL/OPG ratio was calculated.ResultsAccording to the intragroup analysis, there were no statistically significant differences between the preoperative and postoperative levels of the RANKL/OPG ratio in any of the groups. Intergroup analyses showed that there were no statistically significant differences among the Ca(OH)2, Ca(OH)2 + ibuprofen, Ca(OH)2 + ciprofloxacin groups in terms of the percentage change in RANKL/OPG levels before and after treatment.ConclusionsWithin the limitations of the present study, it can be concluded that addition of ibuprofen or ciprofloxacin to Ca(OH)2 paste does not provide any extra benefit in terms of lowering RANKL and OPG levels.  相似文献   
2.
分析丁丙诺啡透皮贴在髋关节置换术患者中的镇痛效果及对骨保护素/受体活化因子(OPG/RANKL)、炎症因子水平的影响。80例髋关节置换术患者按药物不同分为对照组(n=40)和观察组(n=40)。对照组患者给予氯诺昔康(8 mg/次,每日2次),观察组患者给予丁丙诺啡透皮贴(5 mg)。治疗结果表明两组患者在术后4 h、16 h及1天的VAS评分方面差异无统计学意义,而术后2天和术后7天观察组患者的视觉模拟评分(VAS评分)明显低于对照组患者(P<0.05);两组患者术后OPG均明显升高而RANKL和炎症因子C反应蛋白(CRP)、同型半胱氨酸(Hcy)、白细胞介素1β(IL1β)及白细胞介素2(IL2)水平均明显降低(P<0.05),且观察组患者的上述指标变化比对照组患者更显著(P<0.05)。因此,丁丙诺啡透皮贴对髋关节置换术患者中的镇痛效果长效,且能明显降低血清中OPG/RANKL、炎症因子水平。  相似文献   
3.
4.
5.
Osteoporosis is a major public health problem with serious long-term complications. In children, the definition of osteoporosis is not only based on densitometric criteria but also takes into account vertebral and long bone fragility fractures. Several factors, such as long-term high-dose steroids, chronic inflammation, malnutrition, immobility, lack of sex steroids, and medication can reduce bone density and increase the risk for fragility fractures when left untreated. Also, genetic conditions can predispose to primary bone fragility disorders, with osteogenesis imperfecta being the most common. Furthermore, since the growing skeleton is at an increased rate of bone remodeling, the ability to heal long bone fractures and reshape vertebral fractures differentiates children from adults. The scope of this chapter is to review the risk factors of osteoporosis and fragility fractures and describe the commonest causes of primary and secondary osteoporosis and their management in children and young adults.  相似文献   
6.
7.
目的观察仲黄颗粒配合腰椎后路椎间融合术(posterior lumbar interbody fusion,PLIF)治疗合并骨量减少的肝肾亏虚型腰椎间盘突出症的临床疗效,进一步探讨该方法的临床作用机理。方法选取自2014年5月至2017年6月,日照市中医医院共收治的合并骨量减少的肝肾亏虚型腰椎间盘突出症患者96例,其中治疗组48例采用PLIF术后配合仲黄颗粒口服治疗;对照组48例采用PLIF术治疗。分别记录治疗前和治疗后6个月、12个月Oswestry功能障碍指数(oswestry disability index,ODI)评分、骨密度T值及血清骨保护素(osteoprotegerin,OPG)水平三方面的变化及末次随访时不融合、融合器沉降及螺钉松动不良事件。结果治疗组和对照组分别有42例、40例患者获得随访,两组患者对临床疗效均较为满意,但治疗组满意度高于对照组,两组间差异有统计学意义(P0.05)。结论仲黄颗粒可能通过升高血清OPG提高患者骨密度及术后长期临床疗效,从而减少术后植骨不融合、融合器沉降和螺钉松动不良事件的发生。  相似文献   
8.
Osteoporosis is a disease characterized by low bone mass and progressive destruction of bone microstructure, resulting in increasing the risk of fracture. Icariin (ICA) as a phytoestrogen shows osteogenic effects, and the mechanical stimulation has been demonstrated the improving effect on osteoporosis. The objective of this study was to investigate the effect of ICA in combination with constrained dynamic loading (CDL) stimulation on osteoporosis in ovariectomized (OVX) mice. The serum hormone levels, bone turnover markers, trabecular architecture, ulnar biomechanical properties, and the expression of osteoblast‐related gene (alkaline phosphatase, ALP; osteocalcin, OCN; bone morphogenetic protein‐2, BMP‐2; Collagen I (α1), COL1; osteoprotegerin, OPG) and osteoclast‐related genes (receptor activators of NF‐κB ligand, RANKL; tartrate‐resistant acid phosphatase, TRAP) were analyzed. The results showed that ICA + CDL treatment could increase the osteocalcin (20.85%), estradiol levels (20.61%) and decrease the TRAP activity (26.27%) significantly than CDL treatment. The combined treatment attenuated bone loss and biomechanical decrease more than single use of CDL treatment. ICA + CDL treatment significantly up‐regulated the level of osteoblast‐related gene expression and down‐regulated the osteoclast‐related genes expression; moreover, the combined treatment increased the ratio of OPG/RANKL significantly compared to ICA (72.83%) or CDL (65.63%) treatment alone. The present study demonstrates that icariin in combination with constrained dynamic loading treatment may have a therapeutic advantage over constrained dynamic loading treatment alone for the treatment of osteoporosis, which would provide new evidence for the clinical treatment of osteoporosis. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1415–1424, 2018.
  相似文献   
9.
10.
Recent advances in adjuvant treatment have improved progression-free and overall survival in patients with early stage breast cancer. However, up to one third of women will experience tumour recurrence, with bone being a common metastatic site. Current treatment options for metastases to bone comprise systemic antitumour therapy, irradiation, surgery and biphosphonates. As osteoclast activation is mediated by the receptor activator of NF-κB (RANK)/RANK ligand pathway and inhibited by osteoprotegerin (OPG), it was suggested that inhibition of this system may treat bone metastases. Recombinant Fc-OPG was evaluated in women with osteoporosis and malignant bone disease. The fully human antibody denosumab has demonstrated superior activity in reducing markers of bone turnover; therefore this drug was further developed in clinical settings. In advanced breast cancer, denosumab reduced urinary-N-telopeptide:creatinine ratio with potentially fewer side effects compared with bisphosphonates. Proof of direct antitumor activity is missing. Here we review the development and current status of denosumab in breast cancer. Data were obtained by searching the Medline database and abstracts from the American Society for Clinical Oncology (ASCO) annual meeting, European Cancer organization (ECCO), European Society for Medical Oncology (ESMO) and the San Antonio Breast Cancer Symposium, using search terms including bone metastases, bisphosphonates, breast cancer, denosumab, osteoprotegerin, RANK and skeletal-related events.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号